• Age 18-70 years old, ECOG score 0-2; (including those aged 18 and 70);

• Pre-survival time \> 6 months;

• The pathological tissue was confirmed as NK/T cell lymphoma (the pathological report of the first three months of enrollment could be accepted) (Note: If there is any doubt about the pathological diagnosis, domestic third-party consultation could be organized);

• Clinical stage Ⅰ to Ⅱ (CA stage) with at least one measurable lesion;

• Acceptable hematological indicators, no contraindications to chemotherapy; Neutrophil absolute value ≥1.0×10\^9 /L, platelet ≥75×10\^9 /L, hemoglobin ≥80g/L (except patients with lymphoma bone marrow infiltration);

• Liver function: direct bilirubin ≤1.5× upper limit reference value; Glutamic pyruvic transaminase or glutamic oxalacetic transaminase ≤2.5× upper limit reference value; Alkaline phosphatase ≤3×ULN in non-bone invaded patients;

• Renal function: serum creatinine ≤1.5×ULN;

• Female and male patients of reproductive age and their spouses are willing to use adequate contraception throughout the study period, and female patients of reproductive age must have a negative serum pregnancy test within 7 days before the first dose;

• The newly treated patient had not received other tumor-related treatment in the past;

⁃ Subjects voluntarily participate in the clinical trial, sign informed consent, and cooperate with follow-up;